Posts Tagged ‘grants’
Monday, July 2nd, 2012
Innovation Works, the Ben Franklin Technology Partner of Southwestern PA, a statewide economic development organization that supports technology commercialization and company growth through innovation, will award up to $800,000 in technology commercialization funding to universities, early-stage and/or established companies based in Pennsylvania.
Draft proposal submissions for funding through the Technology Commercialization Initiative are due August 3, 2012 with final proposal submissions due September 7, 2012.
Through a competitive selection process, funding will be awarded for individual projects ranging up to $100,000 each that address key engineering design challenges, show a high degree of innovation and most importantly, identify a clear path to commercialization with the potential to significantly impact digital and/or robotics-related companies in Pennsylvania.
Required project completion is 12 months commencing from date of contract.
“The Technology Commercialization Initiative aims to establish and grow a leading industry presence in Pennsylvania focused on market segments in digital multimedia, digital networking, and robotic applications,” said Chuck Brandt, Ph.D., vice president, Technology Programs for Innovation Works.
“We are driving rapid and continuing progress in technology development and commercialization in these areas. Our project funding helps to identify technology challenges within these market segments and create prototype solutions that reach beyond the current generation of available products and services,” continued Dr. Brandt.
The full Request for Proposals can be downloaded from the homepage of Innovation Works website at: www.innovationworks.org. Visitors will be to be redirected to http://www.techcollaborative.org/default.aspx?id=download_rfp.
Commercial submissions will only be accepted from PA firms that have either: a) not previously received Technology Commercialization Initiative (TCI) funding from predecessor organization The Technology Collaborative, or b) received less than $250k of total funding, as prime- and/or subcontractor, from prior TTC TCI solicitations.
Potential applicants should check the Innovation Works website periodically for date(s) for webinars and/or location(s) of proposal workshops to take place throughout the state. These briefings will provide a detailed overview of the submission and evaluation process, as well as a forum for more information. Workshop attendance is not mandatory for submitting a proposal.
Those seeking funding can find more examples of funded projects and information on the website, or contact Chuck Brandt, Ph.D., VP Technology Programs, firstname.lastname@example.org.
Innovation Works assumed responsibility for the Technology Commercialization Initiative (TCI) when it assumed the primary programs of The Technology Collaborative in May.
The Technology Collaborative is ending operations, but funding for the TCI continues at Innovation Works as well as other support for the state’s digital and robotics industry cluster.
Monday, March 21st, 2011
NASHVILLE, TN – Eight startups have won Tennessee Technology Development proof-of-concept grants of $50,000 each.
The companies include 4D Medical Systems, Oak Ridge; Foundation Instruments, Collierville; LED North America; Nutraceutical Discoveries; Phenotype Screening Corp.,Nashiville; The University of Tennessee Research Foundation (2 grants); Venture Incite and Y12 National Security Complex.
For background information on the companies see: Company descriptions.
Founders of the winning firms told Milt Capps of Venture Nashville the grants will help them achieve a number of goals, from refining their software to achieving scale.
TTDC President Leslie Wisner Lynch told Capps the grants also increase the chances of the winning firms receiving future venture capital.
Applicants for the grants must be affiliated with Oak Ridge National Laboratory, St. Jude Children’s Research Hospital, the Tennessee Board of Regents, the Tennessee Independent Colleges and Universities Association, the University of Tennessee System, Vanderbilt University and-or the Y-12 National Security Research Complex.
Wednesday, February 16th, 2011
With nearly 20 percent of the country out of a job, take the road less traveled: start a company. “Startup: The Complete Handbook for Launching a Company for Less,” is a new book that shows entrepreneurs how to start a business on a shoestring budget.
Edwards has written a modern textbook for entrepreneurship, covering all aspects of starting a business. In concise, plain English, “Startup” explains the finer points of branding, advertising, venture funding, grants, SBA loans, patents and business law.
Part manual, part manifesto, the nearly 400-page handbook is packed full of templates, do-it-yourself tools, and proven strategies for bootstrapping.
“I heartily recommend this book,” says Bill Payne, founding member of the Angel Capital Association, Tech Coast Angels, and an Entrepreneur In Residence at the Kauffman Foundation. “Elizabeth does a great job of explaining how to start your company for less – and why it costs less to start companies today than ever before. She offers great tips on personal finance and provides a detailed listing of sources of capital for startups,” says Payne.
“Startup” tackles both strategy and tactics – discussing high-level business strategy concepts and illustrating back-of-the-napkin calculations to help entrepreneurs make good decisions. Edwards offers three tests for feasibility (to minimize risk), 14 creative ways to finance a startup, and a formulaic approach to marketing (to grow revenue). The book also outlines a $20,000 personal financial makeover and tips for getting individual health insurance.
“On average, entrepreneurs are six times wealthier than their employed peers, so we know that the risk and the effort pays off. But most startups – and even mature businesses – are challenged with how to create a profitable business model, conserve cash, and get operational fast. That’s the focus of this book,” says Edwards.
“Most startup books are either not comprehensive or simply outdated, given the rapid change we’ve seen in the startup landscape in recent years. This is more than a guide; it’s a startup bible,” says Michael Cerda, VP of Technology at MySpace, former Entrepreneur in Residence at Venrock, and author of Cerdafied.
The book is available on Amazon.com, www.elizabethedwards.com, on the Kindle, and will debut in major bookstores in the spring.
Elizabeth Edwards serves on the board of the Greater Cincinnati Venture Association and teaches at Xavier University. She has been featured in more than 50 media outlets, including the Wall Street Journal, Business Insider, and BoingBoing, and is a popular speaker at universities and conferences. Follow Edwards on Twitter @eedwards.
Monday, February 7th, 2011
COLUMBIA, MD – The Maryland Technology Development Corporation (TEDCO), in collaboration with the Frederick County Office of Economic Development, have completed the Ft. Detrick Technology Transfer Initiative (FDTTI) and three final grant awardees.
Through the FDTTI program, 26 startup companies received a total of $1,300,000 for the development of technology solutions used to address medical needs of the U.S. Army. The final companies to receive funding are Oculearn, Fyodor Biotechnologies Inc., and Foxspire.
Each research team received $50,000.
The FDTTI program announced by Senator Barbara Mikulski in March 2005, allowed TEDCO to work with the U.S. Army Medical Research and Materiel Command to maintain awareness of new and developing technologies and to develop effective strategies for the transition of successful projects to follow-on funding.
The initial phase of the program provided funding for 11 companies, while the second phase of the program awarded funding to 15 different companies.
Oculearn,– Located in Mount Airy, Md., has designed technology to assist victims of Traumatic Brain Injuries (TBI) who have had services for their injuries discontinued due to limitation of benefits or due to the lack of improvement achieved during rehabilitation.
Fyodor Biotechnologies Inc. – Baltimore-based Fyodor Biotechnologies, Inc. collaborated with the Walter Reed Army Institute of Research (WRAIR) to test, further develop and commercialize its single and recombinant antibody-based urine test for rapid diagnosis of clinical malaria.
Foxspire – Located in Frederick, Md., Foxspire, LCC is working with USAMRMC to design and develop a system that tracks stock of infectious agents.
Thursday, December 16th, 2010
RESEARCH TRIANGLE PARK, NC – Precision BioSciences Inc. has been awarded over $3 million across four government grants. These grants were each awarded to Precision during the 4th Quarter of 2010 and came from the National Institute of Standards and Technology, the Treasury Department, the National Institute of Health, and the State of North Carolina.
Together, the grant funding will allow Precision to accelerate development of its proprietary genome engineering technology called the Directed Nuclease Editor (DNE).
“Precision is poised to utilize DNE technology to address major challenges facing the biomanufacturing industry,” said Michael Nicholson, director of cell biology at Precision BioSciences. “These grants will enable us to further refine applications of the technology, particularly as it pertains to cell line engineering.”
Precision’s proprietary DNE technology enables the production of custom genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.
The company has already produced hundreds of custom endonucleases for partners and internal development that can precisely alter naturally occurring sequences within genomes.
Precision has partnered its DNE technology with several of the world’s largest agbiotech firms and is internally developing applications in biological production and human therapeutics.
Tuesday, October 5th, 2010
BALTIMORE – Profectus BioSciences Inc., a company developing vaccines to treat and prevent chronic viral diseases such as AIDS, has won $3.1 million in National Institute of Health grants. The company also received NIH collaborative grants to Dr. Robert Gallo, director of the Institute of Human Virology of the University of Maryland School of Medicine.
The grants support the development of the company’s Transition State Vaccine (TSV) technology for a prophylactic HIV Vaccine.
The company harnesses the human immune system to treat and prevent viral diseases and cancers via its proprietary vaccines.
Originally developed at the IHV, the TSV strategy targets the adaptive immune response to the most protected portions of HIV envelope spikes that are considered the “Achilles heel” of all HIV isolates.
The TSV is being developed as a subunit protein and also for delivery utilizing the Company’s plasmid DNA and recombinant Vesicular Stomatitis Virus vaccine vectors. Thus far, the TSV approach has generated significant protective responses in several non-human primate models for HIV.
Its unfortunate that many attempts to develop an effective HIV vaccine have so far had poor results in human trials. New approaches–such as that of Profectus, may eventually have better results.
Numerous Southeast companies are working on ways to fire up the human immune system to battle cancers. While results have been promising for some, the slow movement through the pre-clinical and clinical trial process means we probably won’t see any of them hit the market for a good many years yet.
But we think the increased knowledge of how to bring the immune system to bear on fighting AIDS, cancers, and other diseases is going to have revolutionary results in future medicine.
To email TJS Editor/writer Allan Maurer: Allan at TechJournalSouth dot com.
Friday, April 30th, 2010
ORLANDO, FL - Planar Energy, the developer of large-format, solid-state, ceramic-like batteries at half the cost and triple the performance of lithium-ion batteries, today received a $4 million award from the U.S. Department of Energy.
The grant is part of the DOE’s Advanced Research Project Agency-Energy (ARPA-E) initiative to accelerate transformational energy research projects.
“With our breakthrough technology, which couples a fundamental electrolyte materials innovation with our proprietary low-cost, chemical deposition platform and manufacturing process, Planar Energy is creating scalable, environmentally friendly and cost-effective technology that will enable the U.S. transportation industry to reduce reliance on fossil fuels, help reduce greenhouse gas emissions, and reestablish U.S. leadership in energy storage,” said President and CEO Scott Faris.
He added that the DOE award will enable Planar Energy to accelerate the development and commercialization of all solid-state lithium batteries, which will encourage the adoption of plug-in hybrid and all-electric vehicles.
Planar Energy was established in Orlando, Fla., in 2007. It was spun out of the U.S. Department of Energy’s National Renewable Energy Laboratory in Golden, Colo., by Princeton, N.J.-based Battelle Ventures and its Knoxville, Tenn.-based affiliate fund, Innovation Valley Partners.
Wednesday, April 7th, 2010
Duke's Comprehensive Cancer Center
RESEARCH TRIANGLE, NC – Researchers from the University of North Carolina at Chapel Hill, Duke University and N.C. State University have been awarded a $12.5 million, five-year grant from the National Cancer Institute to develop new methods for the design and analysis of cancer clinical trials.
“Statistical Methods for Cancer Clinical Trials,” is one of the largest grants of its kind to be awarded by the National Cancer Institute. The project is led by three principal investigators: Michael R. Kosorok, Ph.D., professor and chair of the biostatistics department of the UNC Gillings School of Global Public Health; Marie Davidian, Ph.D., William Neal Reynolds Professor of Statistics and director of the Center for Quantitative Sciences in Biomedicine at NC State; and Stephen L. George, Ph.D., professor of biostatistics at Duke.
The project will support a major collaborative, multidisciplinary effort that takes advantage of the unrivaled concentration of leading statistical and clinical experts at the three campuses, as well as the two highly-rated cancer centers at UNC and Duke.
Clinical trials are controlled studies in humans that evaluate the value of prevention, diagnosis or treatment methods, such as chemotherapy, radiotherapy or surgery. The effectiveness of almost all advances in cancer treatment must be evaluated in clinical trials before being adopted in clinical practice.
Statisticians play an integral role in designing trials, analyzing and interpreting the results to determine if they are meaningful and developing new methods for design and analysis in settings where traditional methods are inappropriate.
The goal of the project is to dramatically improve the efficiency of the cancer clinical trial process and ultimately to improve the health and longevity of cancer patients.
Thursday, March 18th, 2010
DURHAM, NC – Duke University has received a $10.2 million grant from the Robertson Foundation to create a Translational Cell Therapy Center. The center will focus on the University’s cell therapy research and treatment programs.
The center will look at treatments for cancer, cerebral palsy, stroke, and brain injuries.
“The emerging field of regenerative medicine has great promise, and this generous gift will accelerate the pace of Dr. Kurtzberg’s and other Duke scientists’ world-renowned, translational work in cell therapies,” said Dr. Victor Dzau, Duke chancellor for health affairs and CEO of the Duke University Health System.
“The creation of the TCTC will support the work of many Duke researchers exploring various applications of cell-based therapies,” he added.
Duke researchers have spent decades studying the therapeutic use of umbilical cord blood stem cells, which have the ability to develop into various types of specific cells.
Duke will use part of the foundation grant to create a laboratory where the cells can be harvested and stored.
Friday, March 12th, 2010
ROCKVILLE, MD – Zyngenia Inc., biotherapeutics company focused on next-generation antibody drug development, has received $2.5 million from Maryland and Montgomery County. The state provided a $1 million loan to assist the company with costs of its new 14,000-square-foot facility, while the county provided a $1.5 million grant to help it meet fund-raising goals.
Founded in 2008, Zyngenia raised a $10 million in Series A funding from New Enterprise Associates in November 2009.
The company will initially focus on various cancers and autoimmune diseases.
It uses proprietary technology to enable the development of singular molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into one protein (known as a Zybody.)
At the time of its Series A round in November, Peter Kiener, CEO said, “Zyngenia’s technology platform, developed by Carlos Barbas of The Scripps Institute, is very compelling due to its ability to create biologics that are single protein-combination therapeutics in a manner that is likely to be scientifically, medically, and economically transforming.”
Kiener and several other members of the company’s founding management team hail from MedImmune and MedImmune Ventures.